Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutics Report 2016 - Pipeline Review of 10 Companies & 26 Molecules - Research and Markets

Research and Markets
Posted on: 24 Oct 16

Research and Markets has announced the addition of the "5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016" report to their offering.

5-Hydroxytryptamine Receptor-6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 26 molecules. Out of which approximately 25 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 1, 13 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2016, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity.

Key Topics Covered:

  1. Introduction
  2. 5-Hydroxytryptamine Receptor 6 Overview
  3. Therapeutics Development
  4. Pipeline Products for 5-Hydroxytryptamine Receptor 6 - Overview
  5. Pipeline Products for 5-Hydroxytryptamine Receptor 6 - Comparative Analysis
  6. 5-Hydroxytryptamine Receptor 6 - Therapeutics under Development by Companies
  7. 5-Hydroxytryptamine Receptor 6 - Therapeutics under Investigation by Universities/Institutes
  8. 5-Hydroxytryptamine Receptor 6 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. 5-Hydroxytryptamine Receptor 6 - Products under Development by Companies
  13. 5-Hydroxytryptamine Receptor 6 - Products under Investigation by Universities/Institutes
  14. 5-Hydroxytryptamine Receptor 6 - Companies Involved in Therapeutics Development
  • Adamed Sp. z o.o.
  • Avineuro Pharmaceuticals, Inc.
  • Axovant Sciences Ltd.
  • Biotie Therapies Corp.
  • Celon Pharma Sp. z o.o.
  • Galenea Corp.
  • H. Lundbeck A/S
  • Reviva Pharmaceuticals Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/pvqn83/5hydroxytryptamin

View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006378/en/

Business Wire
www.businesswire.com

Last updated on: 24/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.